Onesource Specialty Pharma balance sheet

As of Sep 2026

Total assets: ₹8,586cr+7.1% on Sep 2025
Shareholders' equity: ₹5,921cr+0.3% on Sep 2025
Total debt: ₹1,484cr+39.2% on Sep 2025
Cash and investments: ₹19.8cr−81.6% on Sep 2025

₹ crore except per share

Tap a line for its trend	H1 FY27Sep 2026	FY26Mar 2026	FY25Mar 2025

Non-current assets
	1,188	926	897
	141	314	60.4
	3,828	3,828	3,828
	1,208	1,264	1,393
	222	215	158
	11.5	10.2	6.9
	0.0	0.0	56.2
	17.1	17.1	17.9
	28.6	27.3	81.0
	274	210	47.1
	6,889	6,784	6,464
Current assets
	446	439	158
	5.6	5.5	8.9
	1,033	690	417
	14.2	35.7	156
	18.8	61.9	144
	10.1	16.5	31.3
	1,082	810	758
	170	177	170
	1,697	1,426	1,086
	8,586	8,210	7,550
Equity
	11.5	11.5	11.4
	5,909	5,820	5,869
	5,921	5,831	5,881
	5,921	5,831	5,881
Liabilities
	584	564	219
	267	219	165
	851	783	384
	19.9	18.3	15.8
	125	135	155
	5.8	1.0	1.2
	1,002	937	556
	899	713	552
	536	375	176
	66.6	70.6	109
	1,502	1,158	837
	13.9	0.0	12.2
	1.3	0.0	11.7
	147	284	253
	1,664	1,442	1,114
	2,665	2,379	1,670
	8,586	8,210	7,550
Trade payables — MSME split
	17.0	22.0	176
	519	353	0.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ONESOURCE₹1,577.60

Onesource Specialty Pharma Ltd.

· Pharma & Health

₹ CrorePeersSTAR DIVISLAB GLAND PFIZER POLYMED RAINBOW KIMS JUBLPHARMAMcap ₹18,082 Cr

View

In ₹ Crore except Per Share As of	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Non-current Assets
+ Property, Plant & Equipment	897.4	925.9	1,187.7
+ Capital Work-in-Progress	60.4	313.9	140.8
+ Goodwill	3,827.5	3,827.5	3,827.5
+ Other Intangibles	1,392.6	1,264.0	1,208.2
+ Intangibles under Development	158.0	215.4	221.8
+ Non-current Investments	6.9	10.2	11.5
+ Trade Receivables — Non-current	56.2	0.0	0.0
+ Other Non-current Financial Assets	17.9	17.1	17.1
Non-current Financial Assets	81.0	27.3	28.6
+ Other Non-current Assets	47.1	210.1	273.9
Total Non-current Assets	6,464.1	6,784.1	6,888.6
Current Assets
+ Inventories	158.1	439.0	445.9
+ Current Investments	8.9	5.5	5.6
+ Trade Receivables	416.6	690.2	1,032.9
+ Cash & Cash Equivalents	156.5	35.7	14.2
+ Other Bank Balances	144.4	61.9	18.8
+ Other Current Financial Assets	31.3	16.5	10.1
Current Financial Assets	757.7	809.7	1,081.5
+ Other Current Assets	170.4	177.3	170.1
Total Current Assets	1,086.2	1,425.9	1,697.5
Total Assets	7,550.2	8,210.0	8,586.1
Equity
+ Equity Share Capital	11.4	11.5	11.5
+ Other Equity / Reserves	5,869.1	5,819.8	5,909.4
Equity — Owners of Parent	5,880.6	5,831.3	5,920.9
Total Equity	5,880.6	5,831.3	5,920.9
Liabilities
+ Borrowings — Non-current	219.3	563.7	584.2
+ Other Non-current Financial Liab	164.6	218.9	266.7
Non-current Financial Liabilities	383.9	782.6	850.9
+ Provisions — Non-current	15.8	18.3	19.9
+ Deferred Tax Liabilities	155.2	134.9	125.0
+ Other Non-current Liabilities	1.2	1.0	5.8
Non-current Liabilities	556.1	936.8	1,001.6
+ Borrowings — Current	552.3	712.6	899.4
+ Trade Payables	175.5	374.6	535.5
+ Other Current Financial Liab	109.3	70.6	66.6
Current Financial Liabilities	837.0	1,157.7	1,501.5
+ Provisions — Current	12.2	0.0	13.9
+ Current Tax Liabilities	11.7	0.0	1.3
+ Other Current Liabilities	252.6	284.3	146.9
Current Liabilities	1,113.6	1,442.0	1,663.6
Total Liabilities	1,669.7	2,378.7	2,665.2
Total Equity & Liabilities	7,550.2	8,210.0	8,586.1
Trade Payables — MSME split
+ Dues to Micro & Small — Current	175.5	22.0	17.0
+ Dues to Other Creditors — Current	0.0	352.6	518.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.